ACTRN12609000521224
Completed
未知
Examining the effectiveness, safety and tolerability of 12 weeks of treatment with low-dose quetiapine (100-400 mg/day) in anorexia nervosa patients aged between 15 and 44 years in improving participants' physical and psychological health status
Astra Zeneca Australia0 sites50 target enrollmentJune 30, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Astra Zeneca Australia
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A Diagnostic and Statistical Manual for Psychiatric Disorders IV (DSM\-IV) diagnosis of anorexia nervosa
- •No history of treatment with an atypical antipsychotic, though treatment for less than 7 days was considered acceptable
Exclusion Criteria
- •Treatment with an atypical antipsychotic drug for longer than 7 days, comorbid psychotic illness, history of brain infarction or brain surgery, diabetes, an intelligence quotient (IQ) of less than 70
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Study of Tuberculosis resistant to treatmentHealth Condition 1: J988- Other specified respiratory disordersCTRI/2021/03/032189International Union Against Tuberculosis and Lung Disease
Completed
Not Applicable
To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patientsHaemophiliaHaematological DisordersISRCTN02847428Baxter (Italy)11
Completed
Phase 1
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment PeriodACTRN12622000680763Hope Medicine (Nanjing) Co., Ltd16
Completed
Phase 3
Clinical study on Abhraloha in iron deficiency AnemiaCTRI/2019/01/017303Shree Dhootapapeshwar Limited57
Completed
Phase 3
A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF LORNOXICAM SR 16mg Vs LORNOXICAM 8mg IN ADULT PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEECTRI/2009/091/000297Glenmark Pharmaceuticals Ltd.210